Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 373 followers
Latest posts
Last updated 4 days ago
Reminder: Invitation to Roche’s Investor Event at ASCO 2026
4 days ago
The Roche Investor Relations team would like to invite you to an...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
6 days ago
New giredestrant data from the lidERA study on its potential as a...
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
13 days ago
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with...
Invitation to Roche’s Virtual ADA Investor Event
18 days ago
We are pleased to invite investors and analysts to participate in our...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
18 days ago
PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow...
Invitation to Roche’s Investor Event at ASCO 2026
25 days ago
The Roche Investor Relations team would like to invite you to an...
Reminder: Invitation to Roche’s Diagnostics Day 2026
27 days ago
The Roche Investor Relations team would like to invite you to the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
about 1 month ago
Group sales were +6% at constant exchange rates (CER)1, -5% when reported...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
about 1 month ago
Group sales were +6% at constant exchange rates (CER)1, -5% when reported...
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
about 1 month ago
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of...
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
about 1 month ago
Phase III METEOROID study met its primary endpoint in patients with myelin...
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
about 1 month ago
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a...